[Source: GenomeWeb News] – Precision Antibody said today that it will develop monoclonal antibodies for 20 cancer-related target proteins for a National Cancer Institute program, under an agreement with NCI contractor SAIC-Frederick.
The company will create the standardized, renewable antibodies for the NCI’s Clinical Proteomic Technologies for Cancer (CPTC) project, which is focused on increasing the number of monoclonal antibody reagents that are available for clinical cancer proteomics research.
The CPTC is a five-year, $104 million effort to develop new proteomics tools and technologies to accelerate discovery and clinical research, Columbia, Md.-based Precision Antibody said in a statement.
For more information: Precision Antibody to Develop Monoclonal Antibodies for NCI